Triastek Receives FDA IND Clearance for 3D Printed Medicine for the Treatment of Ulcerative Colitis
PR98886
NANJING, China, Nov. 21, 2022 /PRNewswire=KYODO JBN/ --
-Triastek's third FDA IND clearance for a 3D printed medicine
-T21, a novel potential treatment capable of colon-targeted drug delivery
Triastek, Inc. ("Triastek") a global healthcare company pioneering 3D printing
of pharmaceuticals with its proprietary technology, Melt Extrusion Deposition
(MED®), announced today that it has received clearance for its Investigational
New Drug (IND) application from the United States Food and Drug Administration
(FDA) to initiate clinical studies of the 3D printed medicine, T21, a potential
treatment for ulcerative colitis.
"We are excited to receive IND clearance to begin clinical trials of this
potentially transformative treatment for patients, " said Dr. Senping Cheng,
founder and CEO of Triastek. "Delaying drug release and delivering oral dosage
forms to the colon is challenging, so T21 offers a promising new option for
patients by providing site-specific drug delivery and localized drug effect,
mitigating potential side effects from systemic exposure. We look forward to
advancing this treatment into the clinic and appreciate the FDA's support."
T21 is a novel potential treatment capable of colon-targeted drug delivery.
With a unique 3D dosage form design, T21 can reach the targeted colon segment
of the GI tract, thus permitting use of a lower drug dose than the reference
listed drug, which provides systemic exposure. Made possible by 3D printing,
radio-imaging agents embedded in specific components of the dosage form were
employed in early formulation development to evaluate and confirm the location
of drug release in the GI tract. This novel process can be utilized in the
development of future drugs targeted to specific segments of the GI tract to
increase the efficiency and success rate of product development. The
delayed-release, colon-targeted oral tablet technology platform can not only be
used for developing small molecule drugs, but for peptide drugs as well.
Triastek had already received IND clearance from the FDA for its T19 and T20
products for treatment of rheumatoid arthritis and cardiovascular and clotting
disorders, respectively. Triastek continues to demonstrate the broad
applicability of its MED® technology through the advancement of products that
solve a wide range of drug delivery challenges across multiple therapeutic
areas.
About Triastek
Triastek, Inc. is a global healthcare company, developing medicines with
proprietary, pioneering 3D printing technology. Triastek is dedicated to
revolutionizing the development and manufacturing of pharmaceutical products
and unlocking the next generation of medicine through 3D printing technology.
Its state-of-the-art technology, called Melt-Extrusion Deposition (MED®),
facilitates the development of medicines in a layered construction to enable
controlled and precise release of treatments. This optimized treatment design
helps control when, where and how much medicine is released in the body,
ensuring a more targeted and efficacious delivery.
About Melt-Extrusion Deposition (MED®)
Melt-Extrusion Deposition (MED®) 3D printing is an additive manufacturing,
end-to-end technology that continuously converts powder feedstocks into
softened/molten states followed by precise layer-by-layer deposition to produce
objects with well-designed geometric structures.
SOURCE:Triastek, Inc.
Image Attachments Links:
Link: http://asianetnews.net/view-attachment?attach-id=434283
Caption: Triastek’s Colon-targeted Drug Delivery Dosage Form Development
Link: http://asianetnews.net/view-attachment?attach-id=434284
Caption: Triastek’s Three Products Enter the Clinical Development Phase within Two Years
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。